Bayer applies for Regorafenib authorization to treat liver cancer

Bayer applies for Regorafenib authorization to treat liver cancer


German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials. The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal, Germany February 24, 2014.



from Biotech News